Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines

Summary. In neurodegenerative disorders, such as Parkinson's disease, selective neuronal death characterizes clinical signs and symptoms. Recently apoptosis was reported to be a common type of cell death in some disorders, and well-controlled apoptotic cascade is proposed to be a target of neuroprotective therapy. In our studies to find endogenous neurotoxins as a pathogenic factor in Parkinson's disease, dopamine-derived N-methyl(R)salsolinol was found to induce apoptosis in dopamine neurons of rat models of Parkinson's disease. In human dopaminergic SH-SY5Y cells, apoptosis was initiated by decline in mitochondrial membrane potential, and anti-apoptotic Bcl-2 family protein regulated apoptotic signal transduction. In addition, a series of propargylamines were found to prevent apoptosis through stabilization of mitochondrial membrane potential, which also involved Bcl-2. The role of mitochondria and the involvement of Bcl-2 in apoptosis and neuroprotection were clearly demonstrated using isolated mitochondria. These results indicate that mitochondria are the site to determine the cell death induced by neurotoxins and also the neuroprotection by anti-apoptotic propargylamines.

[1]  E. Melamed,et al.  Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Boulton,et al.  Loss of mitochondrial membrane potential is dependent on the apoptotic program activated: Prevention by R‐2HMP , 1999, Journal of neuroscience research.

[3]  A. Boulton,et al.  Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. , 1992, Journal of medicinal chemistry.

[4]  M. Naoi,et al.  Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies , 1996, Brain Research.

[5]  W. Tatton,et al.  Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism , 1991, Journal of neuroscience research.

[6]  T. Chittenden,et al.  Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Mandel,et al.  Gene expression analysis in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R‐apomorphine , 2001, Journal of neurochemistry.

[8]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[9]  Y. Akao,et al.  Transfection‐enforced Bcl‐2 overexpression and an anti‐Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde‐3‐phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N‐methyl(R)salsolinol , 2001, Journal of neurochemistry.

[10]  G. Kroemer,et al.  The Permeability Transition Pore Complex: A Target for Apoptosis Regulation by Caspases and Bcl-2–related Proteins , 1998, The Journal of experimental medicine.

[11]  P. Riederer,et al.  Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium. , 1996, European journal of pharmacology.

[12]  DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. , 1989, Archives of neurology.

[13]  G. Kroemer.  The proto-oncogene Bcl-2 and its role in regulating apoptosis , 1997, Nature Medicine.

[14]  H. Tohgi,et al.  A dopaminergic neurotoxin, (R)‐N‐methylsalsolinol, increases in parkinsonian cerebrospinal fluid , 1996, Annals of neurology.

[15]  Y. Tsujimoto,et al.  Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Y. Mizuno,et al.  Histochemical detection of apoptosis in Parkinson's disease , 1996, Journal of the Neurological Sciences.

[17]  M. Naoi,et al.  Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine , 2001, Journal of Neural Transmission.

[18]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[19]  M. Naoi,et al.  (−)‐Deprenyl Protects Human Dopaminergic Neuroblastoma SH‐SY5Y Cells from Apoptosis Induced by Peroxynitrite and Nitric Oxide , 1998, Journal of neurochemistry.

[20]  Shigeomi Shimizu,et al.  Bcl‐2 family: Life‐or‐death switch , 2000, FEBS letters.

[21]  A. Boulton,et al.  Neurochemical, neuroprotective and neurorescue effects of aliphatic N-methylpropargylamines; new MAO-B inhibitors without amphetamine-like properties. , 1995, Progress in brain research.

[22]  M. Naoi,et al.  Glyceraldehyde-3-phospate dehydrogenase is translocated into nuclei through Golgi apparatus during apoptosis induced by 6-hydroxydopamine in human dopaminergic SH-SY5Y cells , 2002, Neuroscience Letters.

[23]  H. Ichinose,et al.  Changes in cytokines and neurotrophins in Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.

[24]  Y. Akao,et al.  Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. , 2000, Journal of neural transmission. Supplementum.

[25]  E. Jauniaux,et al.  The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture , 2000, Neuroreport.

[26]  T. Takeshima,et al.  Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor , 1998, Neuroreport.

[27]  M. Naoi,et al.  Antiapoptotic Properties of Rasagiline, N‐Propargylamine‐1(R)‐aminoindan, and Its Optical (S)‐Isomer, TV1022 , 2001, Annals of the New York Academy of Sciences.

[28]  M. Naoi,et al.  (R) salsolinol N‐methyltransferase activity increases in parkinsonian lymphocytes , 1998, Annals of neurology.

[29]  M. Youdim,et al.  Pharmacology of rasagiline (N-propargyl-1R-aminoindan). , 1999, Advances in neurology.

[30]  Y. Akao,et al.  Erratum: Apoptosis induced by an endogenous neurotoxin, N- methyl(R)salsolinol, is mediated by activation of caspase 3 (Neuroscience Letters (1999) 267 (153-156) PII: S0304394099003614) , 1999 .

[31]  R. Duvoisin,et al.  Studies on the Oxidation of the Dopaminergic Neurotoxin 1‐Methyl‐4‐Phenyl‐1,2,5,6‐Tetrahydropyridine by Monoamine Oxidase B , 1985, Journal of neurochemistry.

[32]  A. Brossi,et al.  Alkaloids in mammalian tissues. 2. Synthesis of (+)-and (-)-1-substituted-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines. , 1972, Journal of medicinal chemistry.

[33]  H. Ichinose,et al.  Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain , 2000, Journal of Neural Transmission.

[34]  M. Naoi,et al.  A neutral N-methyltransferase activity in the striatum determines the level of an endogenous MPP+-like neurotoxin, 1,2-dimethyl-6,7-dihydroxyisoquinolinium ion, in the substantia nigra of human brains , 1997, Neuroscience Letters.

[35]  L. Benítez-Bribiesca.  [Apoptosis in the pathogenesis and treatment of disease]. , 1995, Gaceta medica de Mexico.

[36]  N. Tatton.  Increased Caspase 3 and Bax Immunoreactivity Accompany Nuclear GAPDH Translocation and Neuronal Apoptosis in Parkinson's Disease , 2000, Experimental Neurology.

[37]  J. Penney,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride Neurotoxicity Is Attenuated in Mice Overexpressing Bcl-2 , 1998, The Journal of Neuroscience.

[38]  Brian J Cummings,et al.  Immunohistochemical evidence for apoptosis in Alzheimer's disease. , 1994, Neuroreport.

[39]  M. Naoi,et al.  An Endogenous Dopaminergic Neurotoxin, N‐Methyl‐(R)‐Salsolinol, Induces DNA Damage in Human Dopaminergic Neuroblastoma SH‐SY5Y Cells , 1997, Journal of neurochemistry.

[40]  W Tatton,et al.  The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo , 2001, Annals of the New York Academy of Sciences.

[41]  K. Jellinger.  Cell death mechanisms in Parkinson's disease , 2000, Journal of Neural Transmission.

[42]  M. Naoi,et al.  Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopamine neurons. , 2000, Toxicology.

[43]  Y. Mizuno,et al.  bcl-2 Protein is increased in the brain from parkinsonian patients , 1996, Neuroscience Letters.

[44]  R. Youle,et al.  Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. , 1991, Biochemical and biophysical research communications.

[45]  E. Shohami,et al.  Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. , 1999, European journal of pharmacology.

[46]  C. Portera-Cailliau,et al.  Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[47]  G. Kroemer,et al.  The mitochondrion in cell death control: certainties and incognita. , 2000, Experimental cell research.

[48]  Masashi Narita,et al.  Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC , 1999, Nature.

[49]  E. Hirsch,et al.  Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Naoi,et al.  Neuroprotection by (−)-deprenyl and related compounds , 1999, Mechanisms of Ageing and Development.

[51]  M. Naoi,et al.  A novel enzyme enantio-selectively synthesizes (R)salsolinol, a precursor of a dopaminergic neurotoxin, N-methyl(R)salsolinol , 1996, Neuroscience Letters.

[52]  S. Kish,et al.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.

[53]  Y. Tsujimoto,et al.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.